Testosterone Treatment Correlated with Less Fatigue and Better Symptom Control in Metastatic Renal Cell Carcinoma Patients, Study Reveals

A recent study revealed that testosterone treatment among male patients with metastatic renal cell carcinoma (RCC) and hypogonadism is correlated with less fatigue and better symptom control during targeted therapy.

Photo: Renal Cell Carcinoma | InStyleHealth


What is a renal cell carcinoma (RCC)?

A renal cell carcinoma (RCC) is also known as hypernephroma, renal adenocarcinoma, or renal, or kidney cancer. This type of cancer is commonly found in adults. It is also a fast-growing cancer and has the tendency to spread to the lungs and surrounding organs.

Kidneys are organs in our body that help get rid of waste while also regulating fluid balance. There are tiny tubes in the kidneys known as tubules. These will help filter the blood, aid in excreting waste, and help make urine. RCC occurs when cancer cells start growing abnormally in the lining of tubules of the kidney.

Researchers did a randomized test on 60 male patients with metastatic clear-cell RCC, normal prostate-specific antigen level, low testosterone level, and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue to either testosterone undecanoate 1,000 mg and targeted therapy or targeted therapy alone.

Average change in fatigue from baseline to 28 days according to the Functional Assessment o Chronic Illness Therapy – Fatigue scale was the primary endpoint, while secondary ones included safety, Functional Assessment of Cancer Therapy – Kidney Symptom Index 19, testosterone serum concentrations, red blood cell count, and hemoglobin level.

The follow-up average was 18.2 months as of the data cutoff on 30th December 2019. Preliminary endpoint was attained based on the significant differences at day 28, favoring testosterone over targeted therapy alone as regards the reduced level of fatigue.

Moreover, there were significant changes in scores indicating improved quality of life with testosterone relative to targeted therapy for Functional Assessment of Cancer Therapy – Kidney Symptom Index 19 disease-related symptoms.

Although non-significant differences were observed in red blood cell count and hemoglobin level between the two cohorts.

Researchers said that fatigue is one of the most prevalent adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC).

 

Source: Am J Clin Oncol 2021;44:137-142

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post